Activation of hepatocyte growth factor by urokinase-type plasminogen activator is ionic strength-dependent

被引:11
|
作者
Mars, WM
Jo, M
Gonias, SL
机构
[1] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA
[2] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA
关键词
epsilon-amino-caproic acid (EACA); hepatocyte growth factor (HGF); HGF receptor (MET); ionic strength; urokinase-type plasminogen activator (u-PA); u-PA receptor (u-PAR);
D O I
10.1042/BJ20042028
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The hepatocyte growth factor (HGF) is a multifunctional cytokine that is produced as latent scHGF (single chain HGF). Various proteases reportedly cleave scHGF to generate the active two-chain form (HGF), including u-PA (urokinase-type plasminogen activator), t-PA (tissue-type plasminogen activator), kallikrein, Factor XIa, Factor XIIa, HGF activator and matriptase. Considerable evidence indicates that, in vivo, u-PA activates scHGF in the liver; however, the in vivo results have not been uniformly supported by in vitro experiments. We now report that cleavage of scHGF by high-molecular-mass u-PA (abbreviated u-PA throughout) is sensitive to ionic strength. scHGF cleavage by u-PA was accelerated as the ionic strength was decreased. This result was equivalent irrespective of whether the predominant anion was chloride or acetate. Lmw-u-PA (low-molecular-mass u-PA) was ineffective at cleaving scHGF, regardless of ionic strength. Although scHGF shares homology with plasminogen, EACA (epsilon-amino-caproic acid) did not regulate u-PA-mediated scHGF cleavage. Soluble HGF receptor (MET) and soluble u-PAR (u-PA receptor) inhibited the scHGF cleavage. These results support a model in which the ability of u-PA to activate scHGF in vivo may be highly dependent on local conditions within the extracellular space.
引用
收藏
页码:311 / 315
页数:5
相关论文
共 50 条
  • [1] Activation of hepatocyte growth factor by the urokinase-type plasminogen activator is dependent upon ionic strength
    Mars, WM
    Gonias, SL
    THROMBOSIS AND HAEMOSTASIS, 2005, 93 (04) : A28 - A28
  • [2] Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor scatter factor
    Ried, S
    Jäger, C
    Jeffers, M
    Vande Woude, GF
    Graeff, H
    Schmitt, M
    Lengyel, E
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (23) : 16377 - 16386
  • [3] Urokinase-type plasminogen activator and hepatocyte growth factor in muscle regeneration
    Koh, TJ
    Nguyen, MH
    Cheng, M
    Sisson, TH
    FASEB JOURNAL, 2006, 20 (04): : A808 - A808
  • [4] Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration
    Sisson, Thomas H.
    Nguyen, Mai-Huong
    Yu, Bi
    Novak, Margaret L.
    Simon, Richard H.
    Koh, Timothy J.
    BLOOD, 2009, 114 (24) : 5052 - 5061
  • [5] Urokinase-type plasminogen activator
    Crippa, Massimo P.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (04): : 690 - 694
  • [6] Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes
    Lin, Y
    Xie, WF
    Chen, YX
    Zhang, X
    Zeng, X
    Qiang, H
    Chen, WZ
    Yang, XJ
    Han, ZG
    Zhang, ZB
    LIVER INTERNATIONAL, 2005, 25 (04) : 796 - 807
  • [7] Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia
    Guo, Hong
    Zhou, Lan-Xia
    Ma, Haizhen
    Liu, Bei
    Cheng, Juan
    Ma, Yun-Yun
    Zhao, Li
    ONCOLOGY LETTERS, 2017, 14 (01) : 383 - 389
  • [8] Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid
    Akinci, Bans
    Terzi, Cem
    Sevindik, Gokmen
    Yuksel, Faize
    Tunc, Ulku Aybuke
    Tunali, Sunay
    Yesil, Sena
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (06) : 844 - 849
  • [9] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and-2 in hepatocellular carcinoma
    Zhou, L
    Hayashi, Y
    Itoh, T
    Wang, WP
    Rui, JA
    Itoh, H
    PATHOLOGY INTERNATIONAL, 2000, 50 (05) : 392 - 397
  • [10] Nuclear translocation of urokinase-type plasminogen activator
    Stepanova, V.
    Kuo, A.
    Higazi, A.
    Yarovoi, S.
    Bdeir, K.
    Cines, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 : 228 - 228